Related Experiment Video
Updated: Jun 7, 2025
10:03
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.5K
Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson's Disease
Yingfei Chen1, Yanan Gu2, Can Cao3
1Grade 2020, Capital Medical University, Beijing, 100069, China.
Neurochemical Research
|November 19, 2024
Summary
Alpha-synuclein aggregates link to Parkinson's disease (PD). Researchers identified interaction partners, primarily involved in energy metabolism, that are down-regulated in PD, suggesting new diagnostic and therapeutic targets.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Alpha-synuclein aggregates are a hallmark of Parkinson's disease (PD), a neurodegenerative disorder.
- Understanding the interactions of alpha-synuclein is crucial for elucidating PD pathogenesis.
Purpose of the Study:
- To identify alpha-synuclein interaction partners involved in Parkinson's disease.
- To explore the role of these partners in energy metabolism and PD pathology.
Main Methods:
- Protein expression and purification of alpha-synuclein.
- Pulldown assays coupled with LC-MS/MS to identify interaction partners.
- Analysis of the GSE205450 dataset, immunostaining, Western blot, and ROC curves.
Main Results:
- 157 potential alpha-synuclein interaction partners were identified.
- Four key proteins (ACO2, ANT1, ATP5F1B, CKB) involved in energy metabolism were confirmed.
- These proteins were down-regulated in PD patients and MPTP-lesioned mice, showing diagnostic potential.
Conclusions:
- Down-regulation of alpha-synuclein interaction partners in energy metabolism contributes to PD pathogenesis.
- Formation of protein aggregates involving ANT1 and alpha-synuclein observed in PD models.
- Identified interaction partners represent potential therapeutic targets for Parkinson's disease.
Related Concept Videos
01:15Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:24Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448